Investors have been left with mixed emotions regarding the stock price performance over the year, as it’s been a mixed bag. Until today this year the stock’s price performance recorded an increase of 10.34%. However, over the last six months, the performance has been weaker by 36.17%. The price of ABVC increased 3.23% over the last 30 days. And in the last five days, it has surged by 14.29%.
The market performance of ABVC BioPharma Inc’s stock has been turbulent in recent times. Over the last year, the company’s stock reached its highest point at $9.60 on 05/09/23, while the lowest value for the same duration was $0.67 on 10/06/23.
52-week price history of ABVC Stock
Examining the 52-week high and low prices can provide valuable insights into a stock’s current status and future performance. ABVC BioPharma Inc’s current trading price is -86.67% away from its 52-week high, while its distance from the 52-week low is 89.94%. The stock’s price range during this time has been between $0.67 and $9.60. The trading volume for the Healthcare sector company’s shares reached about 27.3 million for the day, which was higher than the average daily volume of 1.78 million over the last three months.
Market Capitalization vs. Financial Performance: A Comparative Study
ABVC BioPharma Inc (ABVC) has experienced a quarterly rise of 18.52% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 13.52M and boasts a workforce of 19 employees.
Combining Moving Average and Trading Volume Data for Better Market Insight
Based on Barchart.com data, the company’s moving average over the 100-day period was 1.2969, with a change in price of +0.2000. Similarly, ABVC BioPharma Inc recorded 1,963,386 in trading volume during the last 100 days, posting a change of +18.52%.
ABVC’s Debt-to-Equity Ratio Cause for Concern? An In-Depth Look
The debt-to-equity (D/E) ratio is a significant metric that provides insights into a company’s financial state and market presence. By dividing a company’s current liabilities by its shareholders’ equity, the D/E ratio depicts the extent of debt used by a company to fund its assets relative to the value of its shareholders’ equity. At the time of writing, the total D/E ratio for ABVC stands at 0.28. Similarly, the long-term debt-to-equity ratio is also 0.05.
ABVC Stock Stochastic Average
Today, ABVC BioPharma Inc’s raw stochastic average for the past 50 days stands at 49.02%, indicating a decline from the raw stochastic average of the last 20 days, which was 59.52%. Moreover, the company’s Stochastic %K and %D values over the past 20 days were 24.53% and 11.46% respectively.
